Company news
Bridgebio Pharma, Inc. (NASDAQ:BBIO) news
Every Bridgebio Pharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease ...
August 26, 2026
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 3, 2026
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 1, 2026
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living ...
June 28, 2026
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 7, 2026
BridgeBio to Participate in May and June Investor Conferences
May 6, 2026
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 6, 2026
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
May 5, 2026
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
May 4, 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
April 30, 2026
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Bu...
April 28, 2026
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil K...
April 22, 2026
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
March 30, 2026
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
March 30, 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
March 23, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 11, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
March 4, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
February 24, 2026
BridgeBio to Participate in March Investor Conferences
February 23, 2026
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
February 17, 2026
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Pr...
February 12, 2026
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 27, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 27, 2026
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
January 16, 2026
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Re...
January 14, 2026
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
January 5, 2026
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
January 2, 2026
BridgeBio to Participate in December Investor Conferences
November 25, 2025
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
November 8, 2025
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
November 7, 2025
BridgeBio to Participate in November Investor Conferences
November 4, 2025
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions...
November 3, 2025
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
October 29, 2025
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
October 29, 2025
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
October 28, 2025
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
October 27, 2025
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Result...
October 24, 2025
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
September 28, 2025
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
September 22, 2025
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgi...
September 6, 2025